M&A / Deals Daiichi exits OTC, with $1.55bn unit sale to Suntory PharmaphorumDaiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.M&A / DealsRead full story pharminent April 15, 2026 Pharmaphorum Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies. M&A / DealsRead full story Post navigation Previous: BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debutNext: Parkinson’s charity partners Biognosys on biomarker project Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
